6 Related NICE guidance
-
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer. NICE technology appraisal guidance 208 (2010)
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer. NICE technology appraisal guidance 208 (2010)